XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Xencor Inc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $41.22M | $4.42M | $22.44M | $21.00M | $18.61M | $18.23M | $18.79M | $17.80M | $15.41M | $15.50M | $14.30M | $14.50M | 80.5% | +121.5% |
| Milestone | $10.00M | $0 | $5.80M | $0 | $25.00M | $14.50M | $34.00M | $0 | $0 | $500.00K | $27.50M | $46.00M | 19.5% | -60.0% |
| License | $0 | $100.00K | $0 | $0 | $0 | $0 | $0 | $0 | $8.50M | – | – | – | 0.0% | – |
| Research collaboration | – | – | – | – | – | – | – | $0 | $0 | $0 | – | -$1.30M | – | – |
| Non-Cash Royalty | – | – | – | – | – | – | – | $17.80M | $15.40M | $15.50M | $14.60M | $0 | – | – |
| License Agreement | – | – | – | – | – | – | – | $0 | $8.50M | – | – | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Xencor's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.